Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Infinity PharmaceuticalsCorbus PharmaceuticalsAssembly BiosciencesEnochian BiosciencesAtossa Therapeutics
SymbolNASDAQ:INFINASDAQ:CRBPNASDAQ:ASMBNASDAQ:ENOBNASDAQ:ATOS
Price Information
Current Price$2.85$1.64$4.10$3.07$1.52
52 Week RangeBuyHoldBuyN/ABuy
MarketRank™
Overall Score1.61.71.60.51.2
Analysis Score4.43.23.30.03.5
Community Score2.03.02.30.02.5
Dividend Score0.00.00.00.00.0
Ownership Score0.81.71.71.70.0
Earnings & Valuation Score0.60.60.60.60.0
Analyst Ratings
Consensus RecommendationBuyHoldBuyN/ABuy
Consensus Price Target$9.00$15.69$11.50N/A$7.50
% Upside from Price Target215.79% upside856.55% upside180.49% upsideN/A393.42% upside
Trade Information
Market Cap$252.62 million$205.05 million$164.24 million$146.63 million$183.65 million
Beta2.42.140.610.52.34
Average Volume3,607,27712,948,1581,226,937266,61221,563,744
Sales & Book Value
Annual Revenue$3.05 million$36.14 million$15.96 millionN/AN/A
Price / Sales82.835.6710.29N/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.14 per share$0.10 per share$10.49 per share$3.58 per share$1.37 per share
Price / Book20.3616.400.39N/AN/A
Profitability
Net Income$-47,060,000.00$-71,450,000.00$-97,630,000.00$-11,420,000.00$-17,240,000.00
EPS($0.83)($1.12)($3.72)N/AN/A
Trailing P/E RatioN/AN/AN/A0.00N/A
Forward P/E RatioN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-2,592.65%-2,208.06%-60.14%N/AN/A
Return on Equity (ROE)-1,358.77%-485.45%-18.75%-5.79%-130.58%
Return on Assets (ROA)-81.85%-167.68%-15.89%-5.47%-108.14%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.61%N/A0.04%N/A
Current Ratio4.42%2.06%14.66%7.29%7.23%
Quick Ratio4.42%2.06%14.66%7.29%7.23%
Ownership Information
Institutional Ownership Percentage46.66%67.13%92.23%5.11%6.87%
Insider Ownership Percentage13.77%8.20%7.10%69.60%33.21%
Miscellaneous
Employees25141139104
Shares Outstanding88.64 million125.03 million40.06 million47.76 million120.82 million
Next Earnings Date5/10/2021 (Estimated)5/10/2021 (Estimated)5/6/2021 (Estimated)5/10/2021 (Estimated)5/12/2021 (Estimated)
OptionableOptionableOptionableOptionableNot OptionableNot Optionable
SourceHeadline
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Short Interest Up 52.4% in MarchAtossa Therapeutics, Inc. (NASDAQ:ATOS) Short Interest Up 52.4% in March
americanbankingnews.com - April 17 at 8:54 AM
Think You Need A Good Stock? Look At This Atossa Therapeutics, Inc. (NASDAQ:ATOS) AnalysisThink You Need A Good Stock? Look At This Atossa Therapeutics, Inc. (NASDAQ:ATOS) Analysis
stocksregister.com - April 16 at 10:31 PM
6 Biotech Stocks Under $5 Worth Looking At6 Biotech Stocks Under $5 Worth Looking At
investmentu.com - April 15 at 10:07 AM
Why Buying The Atossa Therapeutics, Inc. (NASDAQ:ATOS) Stock Today Might Make SenseWhy Buying The Atossa Therapeutics, Inc. (NASDAQ:ATOS) Stock Today Might Make Sense
stocksregister.com - April 13 at 7:55 AM
FDA Okays Initiation of Endoxifen Study in Ovarian CancerFDA Okays Initiation of Endoxifen Study in Ovarian Cancer
targetedonc.com - April 12 at 7:40 PM
Atossa Therapeutics (NASDAQ:ATOS) Stock Price Crosses Above 200-Day Moving Average of $1.99Atossa Therapeutics (NASDAQ:ATOS) Stock Price Crosses Above 200-Day Moving Average of $1.99
americanbankingnews.com - April 9 at 3:02 AM
Atossa Therapeutics Announces Ovarian Cancer Patient has Begun Treatment with Oral Endoxifen ...Atossa Therapeutics Announces Ovarian Cancer Patient has Begun Treatment with Oral Endoxifen ...
apnews.com - April 8 at 11:59 AM
Atossa Therapeutics Announces Ovarian Cancer Patient has Begun Treatment with Oral Endoxifen under FDA’s Expanded Access PathwayAtossa Therapeutics Announces Ovarian Cancer Patient has Begun Treatment with Oral Endoxifen under FDA’s Expanded Access Pathway
finance.yahoo.com - April 8 at 11:59 AM
Were Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash WiselyWe're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely
nasdaq.com - April 7 at 5:44 PM
Atossa Therapeutics (NASDAQ:ATOS) Announces Quarterly  Earnings ResultsAtossa Therapeutics (NASDAQ:ATOS) Announces Quarterly Earnings Results
americanbankingnews.com - April 1 at 9:40 AM
Atossa Therapeutics Announces Year End 2020 Financial Results and Provides Corporate UpdateAtossa Therapeutics Announces Year End 2020 Financial Results and Provides Corporate Update
finance.yahoo.com - March 31 at 11:00 AM
Physician-Scientist Steven Quay Provides Open Letter Response to WHO Report: Five Undisputed Facts Support the Laboratory Origin of the COVID VirusPhysician-Scientist Steven Quay Provides Open Letter Response to WHO Report: Five Undisputed Facts Support the Laboratory Origin of the COVID Virus
finance.yahoo.com - March 30 at 2:15 PM
Atossa Therapeutics Announces Pricing of $50.0 Million Registered Direct Offering Priced ...Atossa Therapeutics Announces Pricing of $50.0 Million Registered Direct Offering Priced ...
apnews.com - March 23 at 7:27 AM
Atossa Therapeutics Announces Pricing of $50.0 Million Registered Direct Offering Priced At-The-MarketAtossa Therapeutics Announces Pricing of $50.0 Million Registered Direct Offering Priced At-The-Market
finance.yahoo.com - March 22 at 10:15 AM
ATOS Stock Price: Atossa Therapeutics Inc extends rally on FDA Letter for cancer treatmentATOS Stock Price: Atossa Therapeutics Inc extends rally on FDA Letter for cancer treatment
fxstreet.com - March 12 at 5:06 PM
ATOS Stock Price Increased Over 23% Intraday: Why It HappenedATOS Stock Price Increased Over 23% Intraday: Why It Happened
pulse2.com - March 11 at 12:39 PM
Thinking about buying stock in Entera Bio, Atossa Therapeutics, Xpeng, Micron Technology, or Verizon?Thinking about buying stock in Entera Bio, Atossa Therapeutics, Xpeng, Micron Technology, or Verizon?
prnewswire.com - March 11 at 12:39 PM
Atossa Therapeutics Announces Receipt of FDA Safe to Proceed Letter for Treatment of an Ovarian ...Atossa Therapeutics Announces Receipt of FDA Safe to Proceed Letter for Treatment of an Ovarian ...
apnews.com - March 11 at 12:39 PM
Atossa Therapeutics Announces Receipt of FDA Safe to Proceed Letter for Treatment of an Ovarian Cancer Patient with Oral Endoxifen Under Expanded Access PathwayAtossa Therapeutics Announces Receipt of FDA Safe to Proceed Letter for Treatment of an Ovarian Cancer Patient with Oral Endoxifen Under Expanded Access Pathway
finance.yahoo.com - March 11 at 12:39 PM
Atossa’s Nasal Spray Candidate Could Yet Join the Fight Against COVID-19Atossa’s Nasal Spray Candidate Could Yet Join the Fight Against COVID-19
finance.yahoo.com - March 1 at 11:45 AM
Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal SprayAtossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray
bloomberg.com - February 26 at 3:27 AM
Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of  AT-301 Nasal Spray Being Developed for COVID-19Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19
finance.yahoo.com - February 25 at 12:25 PM
Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders ...Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders ...
apnews.com - February 10 at 1:26 PM
Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Accomplishments and Strategy for 2021Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Accomplishments and Strategy for 2021
marketwatch.com - February 10 at 1:26 PM
Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Accomplishments and Strategy for 2021Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Accomplishments and Strategy for 2021
finance.yahoo.com - February 10 at 1:26 PM
DateCompanyBrokerageAction
3/24/2021Infinity PharmaceuticalsTruist SecuritiesInitiated Coverage
3/23/2021Infinity PharmaceuticalsB. RileyLower Price Target
3/23/2021Infinity PharmaceuticalsWells Fargo & CompanyBoost Price Target
3/18/2021Infinity PharmaceuticalsTruist FinancialInitiated Coverage
2/25/2021Infinity PharmaceuticalsPiper SandlerInitiated Coverage
2/11/2021Infinity PharmaceuticalsOppenheimerBoost Price Target
2/5/2021Infinity PharmaceuticalsJPMorgan Chase & Co.Upgrade
6/27/2019Infinity PharmaceuticalsCIBCInitiated Coverage
1/7/2019Infinity PharmaceuticalsUBS GroupReiterated Rating
10/8/2020Corbus PharmaceuticalsHC WainwrightLower Price Target
9/8/2020Corbus PharmaceuticalsJefferies Financial GroupDowngrade
9/8/2020Corbus PharmaceuticalsRoyal Bank of CanadaDowngrade
9/8/2020Corbus PharmaceuticalsBTIG ResearchDowngrade
9/8/2020Corbus PharmaceuticalsRoth CapitalDowngrade
6/4/2020Corbus PharmaceuticalsNomuraBoost Price Target
6/4/2020Corbus PharmaceuticalsNomura InstinetBoost Price Target
3/26/2020Corbus PharmaceuticalsNomura SecuritiesInitiated Coverage
3/29/2021Assembly BiosciencesSVB LeerinkReiterated Rating
2/28/2021Assembly BiosciencesRobert W. BairdReiterated Rating
2/25/2021Assembly BiosciencesMizuhoReiterated Rating
6/25/2020Assembly BiosciencesWilliam BlairReiterated Rating
9/19/2019Assembly BiosciencesChardan CapitalReiterated Rating
9/18/2020Atossa TherapeuticsMaxim GroupReiterated Rating
9/17/2020Atossa TherapeuticsAscendiant Capital MarketsInitiated Coverage
5/15/2018Atossa TherapeuticsNoble FinancialSet Price Target
(Data available from 4/20/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.